Bioactivity Comments

Although peptide sequences for otelixizumab match sequences covered by patents such as US5585097 and US7993641, these do not provide affinity data for the interaction between the antibody and CD3E. We have tagged the primary molecular target based on experimental data contained within the patents and on Bolt et al.'s 1993 article describing development of the antibody [1].

Selectivity at other protein targets
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference CD3e Hs Antibody Binding - - - 1 ⤷ [1]